| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 55.90 | -0.04 (-0.07%) | 39.93 - 58.41 | 3.8 million (Below Avg) |
Market data as of 4:02PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 55.95 |
|---|---|
| Previous Close | 55.94 |
| Day's Range | 55.35 - 56.23 |
| Market Cap | 63.0B |
| Avg Volume (10 Day) | 8.1M |
| Price/Earnings (Trailing 12 Mo.) | 13.4x |
| Earnings Per Share (Trailing 12 Mo.) | 4.17 |
| Dividend Yield | 0.49 (3.51%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Pass |
|---|---|
| Room to increase dividends? | Pass |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Pass |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Lilly Oncology to Release New Pipeline Data at ASCO 2013
PR Newswire - Tuesday 05/14/2013 4:30 PM ET
Lilly Provides Update on CEO Dr. John Lechleiter
PR Newswire - Tuesday 05/14/2013 9:00 AM ET
Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
PR Newswire - Friday 05/10/2013 8:00 AM ET
Retrospective analysis of linagliptin data in sub-populations with type 2 diabetes presented at AACE 22nd Annual Scientific & Clinical Congress
PR Newswire - Monday 05/06/2013 6:38 PM ET
Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery
PR Newswire - Monday 05/06/2013 4:30 PM ET
Lilly Declares Second-Quarter 2013 Dividend
PR Newswire - Monday 05/06/2013 2:30 PM ET
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
PR Newswire - Thursday 05/02/2013 8:00 AM ET
The Importance of Emergency Preparedness: Lilly Diabetes and the American College of Endocrinology (ACE) Help Prep People with Diabetes for Emergencies – Big or Small
Business Wire - Wednesday 05/01/2013 2:58 PM ET
| LLY | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -6.01% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.37 | |
| LT Debt/Equity | 0.30 | |
| Earnings Yield | 7.46% | |
| Price/Sales | 2.79 |
| Company | Last | Change |
|---|---|---|
| Bristol-Myers Squibb Co | 43.30 | +1.24% |
| AbbVie Inc | 47.17 | +2.08% |
| Zoetis Inc | 33.90 | +1.53% |
| Aegerion Pharmaceuticals Inc | 61.57 | -0.21% |
| Impax Laboratories Inc | 18.42 | -1.18% |
Data is delayed by at least 15 min.